Cervical cancer (CC) represents a major public health concern, ranking as the fourth most common cancer among women worldwide. Its primary cause is repeated infection with high-risk human papillomavirus (HPV) strains transmitted through sexual contact. In addition to viral infection, epigenetic modifications, including DNA methylation, histone modification, and noncoding RNA (ncRNA) regulation, play significant roles in cervical carcinogenesis. identifying epigenetic biomarkers is necessary for early diagnosis, prognosis, treatment response prediction, and drug target discovery. Recent clinical trials have demonstrated promising results with different synthetic and natural compounds targeting epigenetic modifications. This chapter discusses in detail the progress of epigenetic therapies targeting DNA methylation, histone modification, and ncRNA regulation in CC. Additionally, this study highlights recent clinical trials investigating epigenetic therapies and biomarkers in CC.